TWI879717B - 治療骨髓增生不良症候群之方法 - Google Patents

治療骨髓增生不良症候群之方法 Download PDF

Info

Publication number
TWI879717B
TWI879717B TW107126009A TW107126009A TWI879717B TW I879717 B TWI879717 B TW I879717B TW 107126009 A TW107126009 A TW 107126009A TW 107126009 A TW107126009 A TW 107126009A TW I879717 B TWI879717 B TW I879717B
Authority
TW
Taiwan
Prior art keywords
mds
imetelstat
weeks
individual
subject
Prior art date
Application number
TW107126009A
Other languages
English (en)
Chinese (zh)
Other versions
TW201919705A (zh
Inventor
亞歷山德拉 里佐
杰奎琳 布索拉里
Original Assignee
美商傑龍公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI879717(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商傑龍公司 filed Critical 美商傑龍公司
Publication of TW201919705A publication Critical patent/TW201919705A/zh
Application granted granted Critical
Publication of TWI879717B publication Critical patent/TWI879717B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107126009A 2017-07-28 2018-07-27 治療骨髓增生不良症候群之方法 TWI879717B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762538315P 2017-07-28 2017-07-28
US62/538,315 2017-07-28
US201762595329P 2017-12-06 2017-12-06
US62/595,329 2017-12-06
US201862685542P 2018-06-15 2018-06-15
US62/685,542 2018-06-15

Publications (2)

Publication Number Publication Date
TW201919705A TW201919705A (zh) 2019-06-01
TWI879717B true TWI879717B (zh) 2025-04-11

Family

ID=63209674

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107126009A TWI879717B (zh) 2017-07-28 2018-07-27 治療骨髓增生不良症候群之方法

Country Status (17)

Country Link
US (1) US12171778B2 (cg-RX-API-DMAC7.html)
EP (1) EP3658156A1 (cg-RX-API-DMAC7.html)
JP (4) JP7316261B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250151565A (cg-RX-API-DMAC7.html)
CN (2) CN121243203A (cg-RX-API-DMAC7.html)
AU (2) AU2018307983B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020001749A2 (cg-RX-API-DMAC7.html)
CA (1) CA3069010A1 (cg-RX-API-DMAC7.html)
CL (2) CL2020000196A1 (cg-RX-API-DMAC7.html)
IL (1) IL272163B1 (cg-RX-API-DMAC7.html)
MA (1) MA49688A (cg-RX-API-DMAC7.html)
MX (1) MX2025005894A (cg-RX-API-DMAC7.html)
SG (1) SG11201913984RA (cg-RX-API-DMAC7.html)
TW (1) TWI879717B (cg-RX-API-DMAC7.html)
UA (1) UA127701C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019023667A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202000070B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN121243203A (zh) 2017-07-28 2026-01-02 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法
CA3120704A1 (en) 2018-11-29 2020-06-04 Geron Corporation Methods of treating myelodysplastic syndrome
KR20230041707A (ko) 2020-07-17 2023-03-24 제론 코포레이션 피하 텔로머라제 억제제 조성물 및 이의 사용 방법

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
EP1210357B1 (en) 1999-09-10 2008-04-02 Geron Corporation Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use
WO2001053307A1 (en) 2000-01-21 2001-07-26 Geron Corporation 2'-arabino-fluorooligonucleotide n3'→p5'phosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
JP4854913B2 (ja) 2001-03-23 2012-01-18 ジェロン・コーポレーション オリゴヌクレオチド結合体
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
EP1694842B1 (en) 2003-11-04 2011-03-23 Geron Corporation Rna amidates and thioamidates for rnai
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
ME02933B (me) 2004-07-02 2018-04-20 Geron Corp Sinteza zaštićenih 3'-amino nukleozionih monomera
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
EP1910342A1 (en) 2005-07-29 2008-04-16 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
US7989428B2 (en) 2006-10-30 2011-08-02 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
ES2407957T3 (es) 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
WO2008153900A1 (en) 2007-06-06 2008-12-18 University Of Florida Research Foundation Kinase inhibitor compounds
CN101220044B (zh) 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
LT3029154T (lt) 2008-10-17 2017-12-27 Geron Corporation Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas
WO2011017096A2 (en) 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
WO2011098901A1 (en) 2010-02-12 2011-08-18 Ipsogen Asxl1 as a new diagnostic marker of myeloid neoplasms
EP2702168B1 (en) 2011-04-29 2018-01-17 Sequenom, Inc. Quantification of a minority nucleic acid species
US20150005250A1 (en) 2011-10-13 2015-01-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Telomerase reverse transcriptase deficiency as diagnostic marker of myelodysplastic syndrome
WO2013059738A2 (en) 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US9593137B2 (en) 2011-12-22 2017-03-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
EP2925889B1 (en) 2012-11-30 2018-09-05 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
HUE049858T2 (hu) 2012-12-07 2020-11-30 Geron Corp A telomerázgátló imetelstat alkalmazása mielodiszpláziás szindróma kezelésére
US20160022708A1 (en) 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
HRP20190538T1 (hr) 2013-11-06 2019-05-17 Mayo Foundation For Medical Education And Research Postupci i materijali za liječenje hematoloških malignosti
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN121243203A (zh) 2017-07-28 2026-01-02 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法

Also Published As

Publication number Publication date
BR112020001749A2 (pt) 2020-07-21
KR102867725B1 (ko) 2025-10-13
CL2021001096A1 (es) 2021-11-12
KR20250151565A (ko) 2025-10-21
IL272163B1 (en) 2025-12-01
AU2018307983A1 (en) 2020-02-13
CL2020000196A1 (es) 2020-11-20
ZA202000070B (en) 2025-09-25
IL272163A (en) 2020-03-31
TW202432146A (zh) 2024-08-16
JP7316261B2 (ja) 2023-07-27
CN121243203A (zh) 2026-01-02
JP2024015000A (ja) 2024-02-01
TW201919705A (zh) 2019-06-01
JP7654761B2 (ja) 2025-04-01
CA3069010A1 (en) 2019-01-31
NZ760873A (en) 2024-03-22
UA127701C2 (uk) 2023-12-06
AU2024219941A1 (en) 2024-10-10
JP2023009229A (ja) 2023-01-19
MA49688A (fr) 2020-06-03
CN110944646A (zh) 2020-03-31
EP3658156A1 (en) 2020-06-03
US20190030064A1 (en) 2019-01-31
JP2020528915A (ja) 2020-10-01
JP2025013669A (ja) 2025-01-24
US12171778B2 (en) 2024-12-24
SG11201913984RA (en) 2020-02-27
JP7654615B2 (ja) 2025-04-01
KR20200033269A (ko) 2020-03-27
WO2019023667A1 (en) 2019-01-31
AU2018307983B2 (en) 2024-07-18
MX2025005894A (es) 2025-06-02

Similar Documents

Publication Publication Date Title
TWI879717B (zh) 治療骨髓增生不良症候群之方法
US20250170160A1 (en) Methods of Treating Myelodysplastic Syndrome
TWI906757B (zh) 治療骨髓增生不良症候群之方法
US20240285773A1 (en) Methods of treating myelodysplastic syndrome and monitoring the treatment
HK40027129A (en) Methods of treating myelodysplastic syndrome
EA050072B1 (ru) Способы лечения миелодиспластического синдрома
EA043524B1 (ru) Способы лечения миелодиспластического синдрома
HK40063245A (en) Methods of treating myelodysplastic syndrome
EA045910B1 (ru) Способы лечения миелодиспластического синдрома